Ad-blockers and privacy-focused browser protections are eroding business analytics at the precise moment when organizations must sharpen their understanding of user behavior to remain competitive.
Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...
Our panel looks at whether smartwatch makers blew it by not focusing on the enterprise, why intent-based networking is the next big thing, whether GPS spoofing is real, and how high is too high when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback